Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers

Robert C. Doebele, Xian Lu, Christopher Sumey, DeLee A. Maxson, Andrew J. Weickhardt, Ana B. Oton, Paul A. Bunn, Anna E. Barón, Wilbur A. Franklin, Dara L. Aisner, Marileila Varella-Garcia, D. Ross Camidge, Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer Cancer. ,vol. 118, pp. 4502- 4511 ,(2012) , 10.1002/CNCR.27409

Norihiro Yamaguchi, Paul A. VanderLaan, Erik Folch, David H. Boucher, Hannah M. Canepa, Michael S. Kent, Sidharta P. Gangadharan, Adnan Majid, Olivier N. Kocher, Michael A. Goldstein, Mark S. Huberman, Daniel B. Costa, Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice Lung Cancer. ,vol. 82, pp. 31- 37 ,(2013) , 10.1016/J.LUNGCAN.2013.07.013

L.E.L. Hendriks, E.F. Smit, B.A.H. Vosse, W.W. Mellema, D.A.M. Heideman, G.P. Bootsma, M. Westenend, C. Pitz, G.J. de Vries, R. Houben, K. Grünberg, M. Bendek, E.-J.M. Speel, A.-M.C. Dingemans, EGFR mutated non-small cell lung cancer patients: More prone to development of bone and brain metastases? Lung Cancer. ,vol. 84, pp. 86- 91 ,(2014) , 10.1016/J.LUNGCAN.2014.01.006

Lakshmi Nayak, Eudocia Quant Lee, Patrick Y. Wen, Epidemiology of Brain Metastases Current Oncology Reports. ,vol. 14, pp. 48- 54 ,(2012) , 10.1007/S11912-011-0203-Y

Stefan Zimmermann, Rafal Dziadziuszko, Solange Peters, Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. Cancer Treatment Reviews. ,vol. 40, pp. 716- 722 ,(2014) , 10.1016/J.CTRV.2014.03.005

Jason P. Fine, Robert J. Gray, A Proportional Hazards Model for the Subdistribution of a Competing Risk Journal of the American Statistical Association. ,vol. 94, pp. 496- 509 ,(1999) , 10.1080/01621459.1999.10474144

David E. Gerber, Leena Gandhi, Daniel B. Costa, Management and future directions in non-small cell lung cancer with known activating mutations. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. ,vol. 34, pp. 353- 365 ,(2014) , 10.14694/EDBOOK_AM.2014.34.E353

Alice T. Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinó, Myung-Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin J. Solomon, Fiona Blackhall, Yi-Long Wu, Michael Thomas, Kenneth J. O'Byrne, Denis Moro-Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne, Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer The New England Journal of Medicine. ,vol. 368, pp. 2385- 2394 ,(2013) , 10.1056/NEJMOA1214886

Paul A. VanderLaan, Norihiro Yamaguchi, Erik Folch, David H. Boucher, Michael S. Kent, Sidharta P. Gangadharan, Adnan Majid, Michael A. Goldstein, Mark S. Huberman, Olivier N. Kocher, Daniel B. Costa, Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer Lung Cancer. ,vol. 84, pp. 39- 44 ,(2014) , 10.1016/J.LUNGCAN.2014.01.013

Rafael Rosell, Enric Carcereny, Radj Gervais, Alain Vergnenegre, Bartomeu Massuti, Enriqueta Felip, Ramon Palmero, Ramon Garcia-Gomez, Cinta Pallares, Jose Miguel Sanchez, Rut Porta, Manuel Cobo, Pilar Garrido, Flavia Longo, Teresa Moran, Amelia Insa, Filippo De Marinis, Romain Corre, Isabel Bover, Alfonso Illiano, Eric Dansin, Javier De Castro, Michele Milella, Noemi Reguart, Giuseppe Altavilla, Ulpiano Jimenez, Mariano Provencio, Miguel Angel Moreno, Josefa Terrasa, Jose Muñoz-Langa, Javier Valdivia, Dolores Isla, Manuel Domine, Olivier Molinier, Julien Mazieres, Nathalie Baize, Rosario Garcia-Campelo, Gilles Robinet, Delvys Rodriguez-Abreu, Guillermo Lopez-Vivanco, Vittorio Gebbia, Lioba Ferrera-Delgado, Pierre Bombaron, Reyes Bernabe, Alessandra Bearz, Angel Artal, Enrico Cortesi, Christian Rolfo, Maria Sanchez-Ronco, Ana Drozdowskyj, Cristina Queralt, Itziar de Aguirre, Jose Luis Ramirez, Jose Javier Sanchez, Miguel Angel Molina, Miquel Taron, Luis Paz-Ares, None, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology. ,vol. 13, pp. 239- 246 ,(2012) , 10.1016/S1470-2045(11)70393-X